Tuzistra Xr is a drug owned by Tris Pharma Inc. It is protected by 2 US drug patents filed in 2015 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2029. Details of Tuzistra Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(3 years from now) | Active |
| US8790700 | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(1 year, 10 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tuzistra Xr's patents.
Latest Legal Activities on Tuzistra Xr's Patents
Given below is the list of recent legal activities going on the following patents of Tuzistra Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jan, 2022 | US8790700 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Jan, 2018 | US8790700 |
| Application ready for PDX access by participating foreign offices Critical | 31 Aug, 2015 | US8790700 |
| Recordation of Patent Grant Mailed Critical | 29 Jul, 2014 | US8790700 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Jul, 2014 | US8790700 |
| Email Notification Critical | 10 Jul, 2014 | US8790700 |
| Issue Notification Mailed Critical | 09 Jul, 2014 | US8790700 |
| Dispatch to FDC | 28 Jun, 2014 | US8790700 |
| Application Is Considered Ready for Issue Critical | 19 Jun, 2014 | US8790700 |
| Printer Rush- No mailing | 18 Jun, 2014 | US8790700 |
US patents provide insights into the exclusivity only within the United States, but Tuzistra Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tuzistra Xr's family patents as well as insights into ongoing legal events on those patents.
Tuzistra Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tuzistra Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 29, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tuzistra Xr Generics:
There are no approved generic versions for Tuzistra Xr as of now.
About Tuzistra Xr
Tuzistra Xr is a drug owned by Tris Pharma Inc. Tuzistra Xr uses Chlorpheniramine Polistirex; Codeine Polistirex as an active ingredient. Tuzistra Xr was launched by Tris Pharma Inc in 2015.
Approval Date:
Tuzistra Xr was approved by FDA for market use on 30 April, 2015.
Active Ingredient:
Tuzistra Xr uses Chlorpheniramine Polistirex; Codeine Polistirex as the active ingredient. Check out other Drugs and Companies using Chlorpheniramine Polistirex; Codeine Polistirex ingredient
Dosage:
Tuzistra Xr is available in suspension, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML | SUSPENSION, EXTENDED RELEASE | Discontinued | ORAL |